NCT04081324View on ClinicalTrials.gov

A Study of Lasmiditan in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 13, 2019

Primary Completion Date

June 15, 2020

Study Completion Date

June 15, 2020

Conditions
Healthy
Interventions
DRUG

Lasmiditan

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (1)

20040

HuaShan Hospital Affiliated To Fudan University, Shanghai

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04081324 - A Study of Lasmiditan in Healthy Chinese Participants | Biotech Hunter | Biotech Hunter